Page 54 - Exact Sciences News Today

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price objective increased by Bank of America from $80.00 to $88.00 in a research note published on Wednesday, The Fly reports. EXAS has been the subject of several other reports. Raymond James downgraded shares of Exact Sciences from an outperform rating to a market perform rating in […]

Exact Sciences (NASDAQ:EXAS – Get Rating) had its target price hoisted by equities research analysts at Citigroup from $90.00 to $100.00 in a report issued on Thursday, The Fly reports. Citigroup’s target price would suggest a potential upside of 27.02% from the company’s previous close. Several other brokerages have also weighed in on EXAS. StockNews.com […]

Biondo Investment Advisors LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 10.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,764 shares of the medical research company’s stock after selling 11,686 shares during […]

TriaGen Wealth Management LLC bought a new position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,109 shares of the medical research company’s stock, valued at approximately $302,000. A number of other large investors have […]

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price target increased by Stifel Nicolaus from $75.00 to $85.00 in a research note published on Wednesday, The Fly reports. Several other brokerages also recently weighed in on EXAS. Piper Sandler increased their price target on Exact Sciences from $50.00 to $70.00 and gave the stock a […]

Craig Hallum upgraded shares of Exact Sciences (NASDAQ:EXAS – Get Rating) from a hold rating to a buy rating in a research report released on Wednesday morning, The Fly reports. The firm currently has $85.00 price objective on the medical research company’s stock, up from their previous price objective of $55.00. Other equities research analysts […]

The cancer diagnostic company's Q1 report was full of good news for shareholders.

EXAS earnings call for the period ending March 31, 2023.

With U.S. stock markets set to open in two hours, Celsius Holdings Inc. (CELH) was up 10.2% in pre-market trading, and Exact Sciences Corp. (EXAS) was up 8.2%.

The cancer screening and diagnostics company posted a narrower-than-expected loss for its first quarter and raised its financial forecasts.